

Proposal

Improving Adherence to Adjuvant Hormonal Therapy Among Disadvantaged Women Diagnosed with Breast Cancer in South Carolina: Proposal for a Multimethod Study

Tisha M Felder^{1,2}, MSW, PhD; Sue P Heiney¹, RN, PhD; James R Hebert^{2,3}, MSPH, ScD; Daniela B Friedman^{4,5}, PhD; Ronit Elk⁶, PhD; Regina Franco⁷, MSN, ANP-C; Lucy Gansauer⁸, CCRP, OCN, RN, MSN; Barbara Christensen⁸, CCRP; Marvella E Ford^{9,10,11,12}, PhD

¹College of Nursing, University of South Carolina, Columbia, SC, United States

²Cancer Prevention & Control Program, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States

³Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States

⁴Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States

⁵Office for the Study of Aging, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States

⁶Center for Palliative and Supportive Care, Division of Geriatrics, Gerontology, and Palliative Care, University of Alabama-Birmingham School of Medicine, Birmingham, AL, United States

⁷Center for Integrative Oncology & Survivorship, Cancer Institute, Prisma Health, Greenville, SC, United States

⁸Gibbs Cancer Center & Research Institute, Spartanburg Regional Healthcare System, Spartanburg, SC, United States

⁹Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States

¹⁰Population Sciences and Cancer Disparities, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States

¹¹Office of Community Outreach and Engagement, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States

¹²SmartState Endowed Chair, Cancer Disparities Research, Medical University of South Carolina and South Carolina State University, Charleston, SC, United States

Corresponding Author:

Tisha M Felder, MSW, PhD
College of Nursing
University of South Carolina
1601 Greene Street
Room 620
Columbia, SC, 29208
United States
Phone: 1 8037779830
Email: feldert@mailbox.sc.edu

Abstract

Background: Current clinical guidelines recommend that hormone receptor–positive breast cancer survivors take adjuvant hormonal therapy (AHT) for 5 to 10 years, following the end of definitive treatment. However, fewer than half of patients adhere to the guidelines, and suboptimal adherence to AHT is associated with an increased risk of breast cancer mortality. Research has extensively documented sociodemographic and disease-specific factors associated with adherence to AHT, but very little evidence exists on behavioral factors (eg, knowledge, patient-provider communication) that can be modified and targeted by interventions.

Objective: The goal of this study is to develop and test a theory-based, multilevel intervention to improve adherence to AHT among breast cancer survivors from racially and socioeconomically disadvantaged backgrounds (eg, Medicaid-insured). The specific aims are to (1) explore multilevel (eg, patient, health care system) factors that influence adherence to AHT; (2) develop a theory-based, multilevel intervention to improve adherence to AHT; and (3) pilot test and evaluate the intervention developed in Aim 2.

Methods: For Aim 1, we will recruit breast cancer survivors and health care professionals to participate in semistructured interviews to gain their perspectives about barriers and facilitators to AHT use. We will conduct a directed content analysis of the Aim 1 qualitative interview data. For Aim 2, we will integrate Aim 1 findings and current literature into the design of a

multilevel intervention using an Intervention Mapping approach. For Aim 3, we will recruit Medicaid-insured breast cancer survivors to assess the feasibility of the pilot intervention.

Results: From May 2016 to July 2018, we completed interviews with 19 breast cancer survivors and 23 health care professionals in South Carolina. We will conduct a directed content analysis of the qualitative interview data. Results from this analysis will be used, in combination with current literature, to design (Aim 2) and pilot test a theory-based multilevel intervention (Aim 3) in Summer 2021. Results of the pilot are expected for Fall 2021.

Conclusions: This study will provide a deeper understanding of how to improve adherence to AHT, using a novel and multilevel approach, among socioeconomically disadvantaged breast cancer survivors who often experience disproportionate breast cancer mortality.

International Registered Report Identifier (IRRID): DERR1-10.2196/17742

(*JMIR Res Protoc* 2020;9(9):e17742) doi: [10.2196/17742](https://doi.org/10.2196/17742)

KEYWORDS

breast neoplasms; medicaid; medication adherence; vulnerable populations; hormonal therapy; endocrine therapy; qualitative methods

Introduction

Background

Adjuvant hormonal therapy (AHT) has been shown to significantly reduce recurrence and mortality rates among women diagnosed with hormone receptor-positive (HR+) breast cancer [1]. Current clinical guidelines for women diagnosed with early stage (stages I-III) HR+ breast cancer recommend up to 10 years of AHT with tamoxifen or an aromatase inhibitor (AI), following surgery, chemotherapy and/or radiation, as indicated. [2,3]. However, although AHT is considered the standard of care for breast cancer, reports show that only about 50% of women complete treatment as recommended [4,5].

Systematic reviews show that sociodemographic factors, such as race and age, are associated with treatment adherence. In contrast, there is limited evidence about psychosocial or behavioral factors that could be targeted with interventions [4,6,7]. Additionally, previous studies that have examined modifiable factors suggest that negative beliefs about AHT, limited social support, low decisional balance scores and poor patient-provider communication are all negatively associated with therapy adherence [8-12]. Early discontinuation of and poor adherence to AHT have been significantly associated with disease progression and increased mortality rates [5,13].

The problem of suboptimal adherence to AHT is important for three key reasons. First, roughly 75% of diagnosed breast cancers are HR+ [14], meaning that adherence to AHT is critical for extending the survival of the majority of breast cancer survivors. Second, studies show that differences in treatment, including AHT use, significantly contribute to persistent racial disparities observed in breast cancer mortality rates between Black and White women [15,16]. This disparity increases for women who are socioeconomically disadvantaged [17,18]. Third, rates of adherence to AHT are lowest among financially disadvantaged populations versus other population-based groups. For example, only 58% of Medicaid-insured women adhered to AHT in the first year [19], compared to 80%-85% in privately insured populations [20,21]. Hershman et al [22] recently found that low annual household income (<US \$40,000) significantly decreased the odds of Black women adhering to

AHT compared to White women. Therefore, the improvement of adherence to AHT among socioeconomically disadvantaged Black women with breast cancer is critical to increase their survival rate as well as to close the gap on racial disparities in breast cancer treatment.

Project Goal and Innovation

The overall goal of this study is to improve adherence to AHT among breast cancer survivors from racially and socioeconomically disadvantaged backgrounds. The specific aims of this study are as follows: (1) explore patient, health care system, and structural factors that may influence adherence to AHT; (2) develop a theory-based, multilevel intervention program to improve adherence to AHT; and (3) pilot and evaluate the intervention program designed in Aim 2.

This project will incorporate principles of health communication theory into the development and testing of the proposed multilevel intervention program. The field of health communication has been nationally prioritized as a strategy to improve individual and population health [23]. Health communications reflect an ecological perspective which posits that individual health beliefs and behaviors are influenced by the broader social environment. Thus, effective public health communication can improve health behaviors by using strategies that consider multiple levels of influence (eg, intrapersonal, interpersonal, community) [24]. The use of health communication theory in this study represents a novel approach to fill a gap in the literature on how to apply theory in multilevel interventions. Furthermore, the application of theory will yield a practical framework for how to use health communication theoretical constructs to determine appropriate communication strategies (eg, knowledge, attitudes) that will target factors at multiple levels known to influence AHT adherence, and how to test them in a multilevel intervention.

Methods

Study Overview

This project received funding from the National Cancer Institute of the National Institutes of Health (2015-2020). The proposed research will address concepts proposed by the World Health

Organization's (WHO) Multidimensional Adherence Model Framework [25] and the Multi-level Context of Cancer Care Model [26] (Table 1). This adapted framework shows how factors are nested within multiple levels to influence AHT adherence and can be useful for designing and targeting

multilevel interventions. The formative, in-depth, semistructured interviews (Aim 1, Years 1-2) will constitute the basis for the development of culturally appropriate messaging and content of the multilevel intervention (Aim 2; Year 2) to be pilot-tested and evaluated in Year 3 (Aim 3).

Table 1. Modifiable factors at multiple levels that influence adherence to adjuvant hormonal therapy [27-29].

| Level and factors | Related factors | Potential interventions |
|-------------------------------------|--|--|
| Patient | <ul style="list-style-type: none"> • Psychosocial factors • Knowledge, beliefs, attitudes • Illness perceptions | <ul style="list-style-type: none"> • Education + behavioral support • Case management • Pharmacist-led, multicomponent intervention |
| Family/social support | <ul style="list-style-type: none"> • Family dynamics • Friends, network support • AHT recommendations | <ul style="list-style-type: none"> • Family/dyadic education • Enhance skill mix/competencies of care team |
| Health care system/health care team | <ul style="list-style-type: none"> • AHT fill interval • Communication preferences/styles • Perceptions/bias • Cost of AHT | <ul style="list-style-type: none"> • Reminders • Education on effective patient-centered communication + behavior management • Reduced out-of-pocket expenses |
| Policy/structural/cultural | <ul style="list-style-type: none"> • National/state/local policy • Distance to health/pharmacy services | <ul style="list-style-type: none"> • Public health insurance coverage |

Aim 1. Explore Patient, Health Care System, and Structural Factors That May Influence Adherence to AHT

Study Design

Study Aim 1 will explore patient, health care system, and structural factors that influence adherence to AHT (Years 1-2). To achieve this aim, in-depth, semistructured qualitative interviews will be conducted with health care professionals who work in oncology settings and with breast cancer survivors. For purposes of this research, we define a "breast cancer survivor" as anyone who has been diagnosed with invasive breast cancer.

Health Care Professional Recruitment and Eligibility

Health care professionals will be recruited to participate in qualitative interviews. The study will target health professionals from key networks and organizations in South Carolina, including professional organizations (eg, oncology nursing, oncology social work), cancer centers and South Carolina's cancer coalition and department of health. The primary method of recruitment will be through email invitation letters sent by

the study's principal investigator (PI). The invitation letter will describe the study aims, study procedures, funding source, and institutional review board approval protocol information. Interested health care professionals will be able to contact the study PI directly by telephone or email. The PI will schedule an interview at a time and location convenient to the potential participants to determine their eligibility for the study. Eligibility requirements will include (1) being employed as a health care professional (ie, physicians, nurses, pharmacists, social workers, patient navigators); (2) currently working with breast cancer patients, for example in an oncology setting, such as a cancer center or hospital; and (3) age ≥ 21 years.

Health Care Professional Data Collection

Before the interview, health care professionals will be asked to complete a brief questionnaire about their personal (eg, gender, age) and professional (eg, current job title, type of health care professional, health care setting) information. The PI will conduct all interviews using a guide developed by the study team. Key topics include: (1) major barriers to AHT adherence; (2) organizational resources to support posttreatment (eg, surgery, chemotherapy) of breast cancer survivors; (3)

communication among health care team members; (4) communication with patients and their families; and (5) organizational strategies for addressing problems with AHT adherence. Participants will receive a US \$50 cash stipend for their time and effort. At the end of the interview, participants will be asked for their contact information if they are willing to participate in a follow-up feedback session, which will serve to inform the development of a subsequent intervention. All interviews will be digitally recorded and field notes will be taken.

Breast Cancer Survivor Recruitment and Eligibility

Breast cancer survivors will be recruited from the South Carolina Oncology Associates (SCOA) and the Gibbs Cancer Center and Research Institute (GCCRI). Eligibility requirements include: (1) age ≥ 21 years; (2) diagnosed with HR+, invasive breast cancer; (3) having medical records that confirm the prescription of any hormonal treatment (anastrozole, exemestane, letrozole, tamoxifen) at any point after diagnosis; (4) eligible for or enrolled in South Carolina Medicaid program; and (5) being able to speak and read in English.

To recruit participants, we will apply a recruitment model developed by Heiney and colleagues [30], which combine social marketing with relationship building. The PI and a research assistant will work with SCOA and GCCRI staff to identify participants who meet the study eligibility criteria using electronic medical records. SCOA patients will be mailed a personal invitation letter from the PI explaining the goals of the study, including a Frequently Asked Questions document that addresses potential concerns of research participants. The letter will include a phone number to call if the participant prefers not to be contacted. Within 3-5 days after the recruitment letter is mailed, the PI or research assistant will contact the participant by phone to provide them with an overview of the study. If the participant expresses interest in the study, the PI or research assistant will verify the participant's study eligibility. If eligibility is met, an interview appointment will be scheduled at a time and location convenient to the participant. If a participant is not eligible, the PI or research assistant will let the participant know that they did not meet the study criteria and will thank them for their interest in participating.

At GCCRI, designated staff will contact potentially eligible breast cancer survivors by phone and provide them with an overview of the study. If the participant shows interest in the study, GCCRI staff will then ensure the participant meets study eligibility. If eligibility is met, GCCRI staff will request verbal consent by phone and set up an interview appointment at GCCRI. Interested and eligible participants will be mailed an "Appointment Form" confirming the date, time, and location of the interview; a copy of the informed consent; and the Frequently Asked Questions document.

Breast Cancer Survivor Data Collection

Interviews with participants recruited from SCOA will be scheduled and conducted at a location (eg, home, library) and time convenient to the participant, while GCCRI participant interviews will be scheduled in person and onsite at GCCRI. Before the interviews, the following informed consent process

will be conducted: a research team member (PI or research assistant) will read aloud a consent form that will inform the participant about the following components of the study: title of the research project, the identity of the project PIs and their respective contact information, an introduction about the study, the aims of the study, reason for the project, a summary of why the individual has been asked to participate, a description of the study procedures (ie, audiotaping of interviews), an outline of any risks and/or benefits, an overview of how confidentiality will be maintained, a discussion of any benefits, and a method of securing additional information or asking questions. After the consent form is read aloud and the participant agrees to participate in the study, the research team member and participant will sign and date the form. Participants will be given a copy of the form for their records.

Following consent, participants will be asked to complete a brief information form about their personal information (eg, age, race, marital status), hormonal therapy (eg, type of drug, daily use), and type of AHT resources used and preferred. The research team will conduct all interviews using a semistructured interview guide. Breast cancer survivors will be asked to describe their experiences with AHT, including experiences communicating with health care professionals about AHT, and strategies used for addressing AHT nonadherence. All participants will be given a US \$50 cash stipend for their time and effort. At the end of the interview, participants will be asked if they are willing to participate in the intervention development phase of this study (Aim 2).

Data Analysis of Interviews

All interviews will be recorded and transcribed verbatim by a professional transcription service. Each participant's audio file and transcript will be assigned the same unique identifier as their corresponding brief questionnaire. Quality control checks will be conducted while reviewing the transcripts to ensure that no personal identifiers are used. Audiotaped transcripts and field notes will be used for data analyses. Transcripts will be independently read and reviewed to check for accuracy and authenticity.

To identify potential modifiable factors and future intervention targets for Aim 2, Assarroudi et al's [31] qualitative content analysis approach will be used to analyze interview transcripts. The PI will develop a preliminary codebook of main categories and subcategories derived from the WHO Multidimensional Adherence Model Framework [25] and Multilevel Context of Cancer Care [26]. The PI will work with other team members to discuss the codebook as well as the final main categories and subcategories and their related meanings. The PI and two other research team members will independently read and code a selection of transcripts using the preliminary codebook. Following this initial coding, all team members will meet, compare coding results, and discuss differences in coding interpretations and concerns with the preliminary codebook. The PI will revise the codebook as needed. Once the codebook is finalized, a research assistant who is knowledgeable in the study topic area will, independently, code all the transcripts, and the PI will code a random sample of the transcripts. The PI and research assistant will then meet and discuss coded

transcripts, reach a consensus among any discrepancies and calculate intercoder agreement [32].

Aim 2. Develop a Theory-based, Multi-level Intervention Program to Improve Adherence to AHT

Overview of Intervention Development Via Data Integration/synthesis and Intervention Mapping

Multiple sources will be used for the development of a theory-based, multilevel intervention program, including findings from Aim 1, current scientific literature, insights from participant feedback sessions (described below), and expertise of the project mentoring team. After analyzing the qualitative data from the breast cancer survivor and health care professional interviews, we will develop a modified, data-informed logic model of potential interventions aimed at health care professionals and their organizations, and survivors and their family/social support. Logic models, representing an outcomes hierarchy, will assist with a broad understanding of the components of each potential intervention [33]. Potential intervention strategies are shown in Table 1 [27-29]. The research team will systematically review and compare findings from the survivor and health care professional qualitative interviews and quantitative questionnaire data. Of interest is not only the variation within the survivor and health care professional groups, but also the variation between the survivor and health care professional reports. We will, therefore, identify themes that occur within and across groups. We will employ a logic model based on the PRECEDE approach [34] to illustrate survivors' experiences with AHT and how knowledge, perceptions and attitudes at different levels impact their ability to adhere to AHT. We will apply appropriate multi-level theories to refine the intervention strategies and messages [35-37].

Validation of Formative Data and Intervention Design Through Participant Feedback Session

From the group of participants that agreed to participate in a follow-up feedback session, we will select a purposive sample of breast cancer survivors (n=5; and their designated family member/friend, n=5) and health care professionals (n=5), based on their brief questionnaire and interview responses. We will host two, 1 to 2 hours feedback sessions: one for breast cancer survivors and their family member/social support, and another one for health care professionals. The feedback sessions will provide participants with the opportunity to judge the accuracy and credibility of the qualitative research findings, as well as to provide alternative interpretations and explanations when necessary [38]. We will also discuss any differences of opinion that may appear between the survivor and health care professional interviews to reach a resolution. Participants will receive US \$50 and a light meal for their time and effort upon

completion of the session. The project mentoring team will provide guidance on how to refine the intervention design based on the data from the feedback sessions and resolve any data discrepancies.

Results

The institutional review boards of the University of South Carolina, Prisma Health (formerly Greenville Health System) and Spartanburg Regional Hospital System reviewed the study protocols for Aim 1 and determined that they were exempt from human research subject regulations. Qualitative data collection for Aim 1 began in May 2016 and has been completed as of July 2018. A total of 19 breast cancer survivors and 23 health care professionals have been interviewed. Qualitative data analysis will be completed by December 2020. Results from this analysis will be used, in addition to current literature, to design (Aim 2) and pilot test a theory-based multilevel intervention (Aim 3) by Summer 2021. Multiple sources will be used for the development of a theory-based, multilevel intervention, including findings from Aim 1, current scientific literature, insights from participant feedback sessions (Aim 2), expertise of the research team, and trainings from the Multilevel Intervention Training Institute at the National Cancer Institute.

Discussion

Findings from this research will help fill a gap in our current understanding of underlying modifiable factors that influence adherence to AHT, particularly among understudied disparate populations [4]. To our knowledge, no previous study has applied a multi-level intervention approach to improve adherence to AHT [39]. Applying this approach to the cancer treatment and survivorship phases of the cancer control continuum is novel because most multi-level research in this area focuses on prevention and screening [26,40]. There is a similar pattern within the field of breast cancer research, where there are fewer intervention studies that focus on improving breast cancer treatment outcomes, compared to screening [41,42]. Among the studies that focus on improving adherence to AHT, few have found significant intervention effects [39,43-45] or are currently analyzing data [46].

In conclusion, achieving the proposed aims will contribute to the scientific community's growing interest in multilevel intervention design and analyses; describe relationships between modifiable patient, family/social support, and health care system/team factors and adherence to AHT; and identify feasible intervention strategies for improving adherence to AHT among breast cancer survivors from racially and socioeconomically disadvantaged backgrounds.

Acknowledgments

TMF was funded by an NCI Mentored Research Scientist Development Award to Promote Diversity (K01CA193667). All opinions expressed herein are the sole responsibility of the authors and do not reflect the views of the National Institutes of Health.

Conflicts of Interest

None declared.

Multimedia Appendix 1

NIH peer reviews.

[\[PDF File \(Adobe PDF File\), 172 KB-Multimedia Appendix 1\]](#)

References

1. Early BCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005;365(9472):1687-1717. [doi: [10.1016/S0140-6736\(05\)66544-0](https://doi.org/10.1016/S0140-6736(05)66544-0)] [Medline: [15894097](https://pubmed.ncbi.nlm.nih.gov/15894097/)]
2. Burstein HJ, Lacchetti C, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. *J Oncol Pract* 2019 Feb;15(2):106-107. [doi: [10.1200/JOP.18.00617](https://doi.org/10.1200/JOP.18.00617)] [Medline: [30523754](https://pubmed.ncbi.nlm.nih.gov/30523754/)]
3. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, et al. NCCN task force report: oral chemotherapy. *J Natl Compr Canc Netw* 2008 Mar;6 Suppl 3:S1-14. [Medline: [18377852](https://pubmed.ncbi.nlm.nih.gov/18377852/)]
4. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. *Breast Cancer Res Treat* 2012 Jul;134(2):459-478 [FREE Full text] [doi: [10.1007/s10549-012-2114-5](https://doi.org/10.1007/s10549-012-2114-5)] [Medline: [22689091](https://pubmed.ncbi.nlm.nih.gov/22689091/)]
5. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. *Breast Cancer Res Treat* 2011 Apr;126(2):529-537 [FREE Full text] [doi: [10.1007/s10549-010-1132-4](https://doi.org/10.1007/s10549-010-1132-4)] [Medline: [20803066](https://pubmed.ncbi.nlm.nih.gov/20803066/)]
6. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. *Cancer Prev Res* 2011 Sep;4(9):1360-1365 [FREE Full text] [doi: [10.1158/1940-6207.CAPR-11-0380](https://doi.org/10.1158/1940-6207.CAPR-11-0380)] [Medline: [21893499](https://pubmed.ncbi.nlm.nih.gov/21893499/)]
7. Banning M. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. *Eur J Cancer Care* 2012 Jan;21(1):10-19. [doi: [10.1111/j.1365-2354.2011.01295.x](https://doi.org/10.1111/j.1365-2354.2011.01295.x)] [Medline: [22004071](https://pubmed.ncbi.nlm.nih.gov/22004071/)]
8. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. *Patient Educ Couns* 2005 Oct;59(1):97-102. [doi: [10.1016/j.pec.2004.10.005](https://doi.org/10.1016/j.pec.2004.10.005)] [Medline: [16198223](https://pubmed.ncbi.nlm.nih.gov/16198223/)]
9. Huiart L, Bouhnik A, Rey D, Tarpin C, Cluze C, Bendiane MK, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? *Eur J Cancer* 2012 Sep;48(13):1939-1946. [doi: [10.1016/j.ejca.2012.03.004](https://doi.org/10.1016/j.ejca.2012.03.004)] [Medline: [22464016](https://pubmed.ncbi.nlm.nih.gov/22464016/)]
10. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. *Breast Cancer Res Treat* 2006 Sep;99(2):215-220. [doi: [10.1007/s10549-006-9193-0](https://doi.org/10.1007/s10549-006-9193-0)] [Medline: [16541307](https://pubmed.ncbi.nlm.nih.gov/16541307/)]
11. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. *J Clin Oncol* 2004 Aug 15;22(16):3309-3315. [doi: [10.1200/JCO.2004.11.064](https://doi.org/10.1200/JCO.2004.11.064)] [Medline: [15310774](https://pubmed.ncbi.nlm.nih.gov/15310774/)]
12. Liu Y, Malin JL, Diamant AL, Thind A, Maly RC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. *Breast Cancer Res Treat* 2013 Feb;137(3):829-836 [FREE Full text] [doi: [10.1007/s10549-012-2387-8](https://doi.org/10.1007/s10549-012-2387-8)] [Medline: [23263740](https://pubmed.ncbi.nlm.nih.gov/23263740/)]
13. Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, et al. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). *Breast Cancer Res Treat* 2012 Jul;134(1):419-428 [FREE Full text] [doi: [10.1007/s10549-012-2066-9](https://doi.org/10.1007/s10549-012-2066-9)] [Medline: [22527111](https://pubmed.ncbi.nlm.nih.gov/22527111/)]
14. Rugo HS. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. *Ann Oncol* 2008 Jan;19(1):16-27 [FREE Full text] [doi: [10.1093/annonc/mdm282](https://doi.org/10.1093/annonc/mdm282)] [Medline: [17693420](https://pubmed.ncbi.nlm.nih.gov/17693420/)]
15. Mandelblatt JS, Sheppard VB, Neugut AI. Black-white differences in breast cancer outcomes among older Medicare beneficiaries: does systemic treatment matter? *JAMA* 2013 Jul 24;310(4):376-377 [FREE Full text] [doi: [10.1001/jama.2013.8273](https://doi.org/10.1001/jama.2013.8273)] [Medline: [23917286](https://pubmed.ncbi.nlm.nih.gov/23917286/)]
16. van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EAM, Stoto MA, Draisma G, et al. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. *Cancer Epidemiol Biomarkers Prev* 2011 Jan;20(1):112-122 [FREE Full text] [doi: [10.1158/1055-9965.EPI-10-0944](https://doi.org/10.1158/1055-9965.EPI-10-0944)] [Medline: [21119071](https://pubmed.ncbi.nlm.nih.gov/21119071/)]
17. Hunt BR, Whitman S, Hurlbert MS. Increasing Black:White disparities in breast cancer mortality in the 50 largest cities in the United States. *Cancer Epidemiol* 2014 Apr;38(2):118-123. [doi: [10.1016/j.canep.2013.09.009](https://doi.org/10.1016/j.canep.2013.09.009)] [Medline: [24602836](https://pubmed.ncbi.nlm.nih.gov/24602836/)]
18. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. *J Womens Health* 2009 Jun;18(6):883-893. [doi: [10.1089/jwh.2008.1127](https://doi.org/10.1089/jwh.2008.1127)] [Medline: [19514831](https://pubmed.ncbi.nlm.nih.gov/19514831/)]
19. Yung RL, Hassett MJ, Chen K, Gesten FC, Roohan PJ, Boscoe FP, et al. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. *J Natl Cancer Inst* 2012 Jul 18;104(14):1102-1105 [FREE Full text] [doi: [10.1093/jnci/djs273](https://doi.org/10.1093/jnci/djs273)] [Medline: [22773822](https://pubmed.ncbi.nlm.nih.gov/22773822/)]
20. Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. *J Clin Oncol* 2006 Mar 20;24(9):1357-1362. [doi: [10.1200/JCO.2005.04.5799](https://doi.org/10.1200/JCO.2005.04.5799)] [Medline: [16549830](https://pubmed.ncbi.nlm.nih.gov/16549830/)]

21. Svahn TH, Niland JC, Carlson RW, Hughes ME, Ottesen RA, Theriault RL, et al. Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer. *J Natl Compr Canc Netw* 2009 Feb;7(2):115-121. [doi: [10.6004/jnccn.2009.0011](https://doi.org/10.6004/jnccn.2009.0011)] [Medline: [19200415](https://pubmed.ncbi.nlm.nih.gov/19200415/)]
22. Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, Neugut AI. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. *J Clin Oncol* 2015 Mar 20;33(9):1053-1059 [FREE Full text] [doi: [10.1200/JCO.2014.58.3062](https://doi.org/10.1200/JCO.2014.58.3062)] [Medline: [25691670](https://pubmed.ncbi.nlm.nih.gov/25691670/)]
23. Healthy People 2020. ODPHP: Office of Disease Prevention and Health Promotion. 2011 Feb 15. URL: <https://www.healthypeople.gov/> [accessed 2020-02-15]
24. Theory at a glance: A guide for health promotion practice. ODPHP: Office of Disease Prevention and Health Promotion. 2005. URL: https://cancercontrol.cancer.gov/brp/research/theories_project/theory.pdf [accessed 2020-02-15]
25. World Health Organization. In: Sabate E, editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
26. Taplin SH, Anhang Price R, Edwards HM, Foster MK, Breslau ES, Chollette V, et al. Introduction: Understanding and influencing multilevel factors across the cancer care continuum. *J Natl Cancer Inst Monogr* 2012 May;2012(44):2-10 [FREE Full text] [doi: [10.1093/jncimonographs/lgs008](https://doi.org/10.1093/jncimonographs/lgs008)] [Medline: [22623590](https://pubmed.ncbi.nlm.nih.gov/22623590/)]
27. Berben L, Dobbels F, Engberg S, Hill MN, De Geest S. An ecological perspective on medication adherence. *West J Nurs Res* 2012 Aug;34(5):635-653. [doi: [10.1177/0193945911434518](https://doi.org/10.1177/0193945911434518)] [Medline: [22309989](https://pubmed.ncbi.nlm.nih.gov/22309989/)]
28. De BL, Matteson M, Dobbels F, Russell C, De GS. Interventions to improve medication-adherence after transplantation: a systematic review. *Transpl Int* 2009 Aug;22(8):780-797 [FREE Full text] [doi: [10.1111/j.1432-2277.2009.00881.x](https://doi.org/10.1111/j.1432-2277.2009.00881.x)] [Medline: [19386076](https://pubmed.ncbi.nlm.nih.gov/19386076/)]
29. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RCM, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. *Ann Intern Med* 2012 Dec 4;157(11):785-795. [doi: [10.7326/0003-4819-157-11-201212040-00538](https://doi.org/10.7326/0003-4819-157-11-201212040-00538)] [Medline: [22964778](https://pubmed.ncbi.nlm.nih.gov/22964778/)]
30. Heiney SP, Adams SA, Wells LM, Johnson H. Evaluation of conceptual framework for recruitment of African American patients with breast cancer. *Oncol Nurs Forum* 2010 May;37(3):E160-E167 [FREE Full text] [doi: [10.1188/10.ONF.E160-E167](https://doi.org/10.1188/10.ONF.E160-E167)] [Medline: [20439201](https://pubmed.ncbi.nlm.nih.gov/20439201/)]
31. Assarroudi A, Heshmati Nabavi F, Armat MR, Ebadi A, Vaismoradi M. Directed qualitative content analysis: the description and elaboration of its underpinning methods and data analysis process. *J Res Nurs* 2018 Jan 10;23(1):42-55. [doi: [10.1177/1744987117741667](https://doi.org/10.1177/1744987117741667)]
32. Campbell JL, Quincy C, Osserman J, Pedersen OK. Coding in-depth semistructured interviews. *Sociol Methods Res* 2013 Aug 21;42(3):294-320. [doi: [10.1177/0049124113500475](https://doi.org/10.1177/0049124113500475)]
33. Osborne RH, Elsworth GR, Whitfield K. The Health Education Impact Questionnaire (heiQ): an outcomes and evaluation measure for patient education and self-management interventions for people with chronic conditions. *Patient Educ Couns* 2007 May;66(2):192-201. [doi: [10.1016/j.pec.2006.12.002](https://doi.org/10.1016/j.pec.2006.12.002)] [Medline: [17320338](https://pubmed.ncbi.nlm.nih.gov/17320338/)]
34. Green LW, Kreuter MW. Health program planning: an educational and ecological approach. New York: McGraw-Hill; 2005.
35. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH. Intervention mapping: designing theory- and evidence-based health promotion programs. Mountain View: Mayfield; 2001.
36. Bartholomew LK, Parcel GS, Kok G. Intervention mapping: a process for developing theory- and evidence-based health education programs. *Health Educ Behav* 1998 Oct;25(5):545-563. [doi: [10.1177/109019819802500502](https://doi.org/10.1177/109019819802500502)] [Medline: [9768376](https://pubmed.ncbi.nlm.nih.gov/9768376/)]
37. Bartholomew LK, Parcel GS, Kok G, Gottlieb NH. Planning health promotion programs: an intervention mapping approach. San Francisco: Jossey-Bass; 2011.
38. Creswell JW. Qualitative inquiry and research design: choosing among five approaches. Los Angeles: SAGE; 2012.
39. Heiney SP, Parker PD, Felder TM, Adams SA, Omofuma OO, Hulett JM. A systematic review of interventions to improve adherence to endocrine therapy. *Breast Cancer Res Treat* 2019 Feb;173(3):499-510. [doi: [10.1007/s10549-018-5012-7](https://doi.org/10.1007/s10549-018-5012-7)] [Medline: [30387003](https://pubmed.ncbi.nlm.nih.gov/30387003/)]
40. Stange KC, Breslau ES, Dietrich AJ, Glasgow RE. State-of-the-art and future directions in multilevel interventions across the cancer control continuum. *J Natl Cancer Inst Monogr* 2012 May;2012(44):20-31 [FREE Full text] [doi: [10.1093/jncimonographs/lgs006](https://doi.org/10.1093/jncimonographs/lgs006)] [Medline: [22623592](https://pubmed.ncbi.nlm.nih.gov/22623592/)]
41. Masi CM, Blackman DJ, Peek ME. Interventions to enhance breast cancer screening, diagnosis, and treatment among racial and ethnic minority women. *Med Care Res Rev* 2007 Oct;64(5 Suppl):195S-242S [FREE Full text] [doi: [10.1177/1077558707305410](https://doi.org/10.1177/1077558707305410)] [Medline: [17881627](https://pubmed.ncbi.nlm.nih.gov/17881627/)]
42. Robinson-White S, Conroy B, Slavish KH, Rosenzweig M. Patient navigation in breast cancer: a systematic review. *Cancer Nurs* 2010;33(2):127-140. [doi: [10.1097/NCC.0b013e3181c40401](https://doi.org/10.1097/NCC.0b013e3181c40401)] [Medline: [20142736](https://pubmed.ncbi.nlm.nih.gov/20142736/)]
43. Albert U, Zemlin C, Hadji P, Ziller V, Kuhler B, Frank-Hahn B, et al. The impact of breast care nurses on patients' satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. *Breast Care* 2011;6(3):221-226 [FREE Full text] [doi: [10.1159/000329006](https://doi.org/10.1159/000329006)] [Medline: [21779228](https://pubmed.ncbi.nlm.nih.gov/21779228/)]
44. Hadji P, Blettner M, Harbeck N, Jackisch C, Lück H, Windemuth-Kieselbach C, et al. The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on

- persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. *Ann Oncol* 2013 Jun;24(6):1505-1512 [[FREE Full text](#)] [doi: [10.1093/annonc/mds653](https://doi.org/10.1093/annonc/mds653)] [Medline: [23378537](#)]
45. Yu K, Zhou Y, Liu G, Li B, He P, Zhang H, et al. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. *Breast Cancer Res Treat* 2012 Jul;134(1):307-313. [doi: [10.1007/s10549-012-2059-8](https://doi.org/10.1007/s10549-012-2059-8)] [Medline: [22527106](#)]
46. He Y, Tan EH, Wong ALA, Tan CC, Wong P, Lee SC, et al. Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder. *BMC Cancer* 2018 Jul 09;18(1):727 [[FREE Full text](#)] [doi: [10.1186/s12885-018-4660-7](https://doi.org/10.1186/s12885-018-4660-7)] [Medline: [29986672](#)]

Abbreviations

AHT: Adjuvant hormonal therapy
GCCRI: Gibbs Cancer Center and Research Institute
HR+: Hormone receptor-positive
PI: Principal investigator
SCOA: South Carolina Oncology Associates
WHO: World Health Organization

Edited by G Eysenbach; submitted 17.02.20; peer-reviewed by A Sutton, R Wassersug; accepted 15.06.20; published 03.09.20

Please cite as:

*Felder TM, Heiney SP, Hebert JR, Friedman DB, Elk R, Franco R, Gansauer L, Christensen B, Ford ME
Improving Adherence to Adjuvant Hormonal Therapy Among Disadvantaged Women Diagnosed with Breast Cancer in South Carolina:
Proposal for a Multimethod Study
JMIR Res Protoc 2020;9(9):e17742
URL: <https://www.researchprotocols.org/2020/9/e17742>
doi: [10.2196/17742](https://doi.org/10.2196/17742)
PMID:*

©Tisha M Felder, Sue P Heiney, James R Hebert, Daniela B Friedman, Ronit Elk, Regina Franco, Lucy Gansauer, Barbara Christensen, Marvella E Ford. Originally published in JMIR Research Protocols (<http://www.researchprotocols.org>), 03.09.2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <http://www.researchprotocols.org>, as well as this copyright and license information must be included.